Cogent 10-Q: Q3 Loss Widens to $111.4M; $791.1M Cash Funds Operations Into Late 2028
COGT has more than doubled off its 52-week low of $13.78.
Summary
Cogent's Q3 10-Q shows a $111.4 million net loss and $791.1 million in cash that management says funds operations into late 2028, past all three bezuclastinib PDUFA dates. Commercial-build spending drove G&A to $42.1 million for the quarter, and $414.6 million remains available under the ATM.
Key Events · Earnings and Guidance · COGT
-
Q3 Net Loss Widens to $111.4M
Net loss was $111.4 million for Q3 2026 versus $80.9 million a year earlier, on operating expenses of $117.2 million (R&D $75.1 million, G&A $42.1 million).
-
Cash Funds Operations Into Late 2028
Cash, cash equivalents and marketable securities totaled $791.1 million at September 30, 2026, which management says covers operating and capex needs into late 2028—past all three pending bezuclastinib PDUFA dates.
-
ATM Adds $117.5M, $414.6M Remaining
3,094,902 shares were sold under the Guggenheim Sales Agreement in the first nine months for net proceeds of about $117.5 million; $414.6 million remained unsold and available as of September 30, 2026.
-
Three PDUFA Dates Ahead
Bezuclastinib action dates are November 30, 2026 (GIST), December 30, 2026 (NonAdvSM) and June 29, 2027 (AdvSM); the company is building commercial infrastructure for a U.S. launch.
Analysis · COGT · Life Sciences
The headline loss was already out via this morning's 8-K, so the real news is in the details. With $791.1 million of cash and securities, Cogent can run into late 2028—past all three bezuclastinib PDUFA dates (November 30, 2026 for GIST, December 30, 2026 for NonAdvSM, June 29, 2027 for AdvSM). That removes any near-term financing need ahead of the binary FDA decisions. The offset is spending: G&A jumped to $42.1 million in the quarter from $14.4 million a year ago as Cogent builds a commercial organization. The company also sold 3,094,902 shares under its ATM for $117.5 million net in the first nine months, leaving $414.6 million available—an overhang that can be tapped if launch costs run higher.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COGT was trading at $29.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $13.78 to $43.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.